Icatibant Teva

Icatibant, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with confirmed HAE and is formulated for rapid subcutaneous administration to quickly alleviate swelling.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring reliable cold‑chain logistics and regulatory compliance for global distribution.

Icatibant is used to manage hereditary angioedema, a disorder characterized by excessive bradykinin‑mediated swelling.

Hereditary angioedema (HAE) type I: reduces swelling and relieves symptoms during acute episodes. Hereditary angioedema (HAE) type II: blocks bradykinin‑induced edema to control attacks. Hereditary angioedema with normal C1‑INH (HAE‑nC1‑INH): provides rapid symptom control in acute attacks.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Localized swelling at the injection site. - Nausea or mild headache. - Dizziness or transient fatigue.

Serious or Rare Side Effects: - Hypersensitivity reactions including anaphylaxis. - Severe hypotension or cardiovascular collapse. - Worsening angioedema or new onset of facial swelling.

When prescribing Icatibant, clinicians should observe several safety considerations.

Hypersensitivity assessment: verify no known allergy to icatibant or formulation components. Monitor for worsening angioedema: observe patient after injection for any increase in swelling. Cardiovascular caution: use carefully in patients with hypotension or cardiac disease. Concurrent bradykinin‑modulating drugs: avoid co‑administration with ACE inhibitors or other B2 antagonists. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin pathway or affect injection site absorption.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate angioedema. - Concurrent use of other bradykinin B2 receptor antagonists: additive blockade can lead to unpredictable effects.

Moderate Interactions (Monitor Closely): - Subcutaneous co‑injections (e.g., insulin): may alter absorption kinetics; monitor efficacy. - Immunosuppressive agents: watch for heightened infection risk. - Anticoagulants (e.g., warfarin): monitor for any changes in bleeding tendency.